Showing results (91-100 of 208) with videos related to

Sort By:
Pageof 21
Health and Quality of Life Outcomes|July 4, 2019
Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional studyRaphaël Busson, Marleen van der Kaaij, Nicolas Mounier, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2022
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple MyelomaFredrik Schjesvold, Bruno Paiva, Vincent Ribrag, et al.
International Journal of Cancer|September 16, 2015
Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experienceCarole Helissey, Pamela Biondani, Florian Roquet, et al.
Leukemia & Lymphoma|July 16, 2010
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conferenceMartin Dreyling, Eva Hoster, Silvia Bea, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2023
Profile and outcome of cancer patients enrolled in contemporary phase I trialsEmily Alouani, Anas Gazzah, Sandrine Mercier, et al.
European Journal of Haematology|December 16, 2019
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II resultJean-Marie Michot, Maxime Annereau, Alina Danu, et al.
Haematologica|January 28, 2017
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studyVincent Ribrag, Won Seog Kim, Reda Bouabdallah, et al.
Blood|January 24, 2014
Perinucleolar relocalization and nucleolin as crucial events in the transcriptional activation of key genes in mantle cell lymphomaJeanne Allinne, Andrei Pichugin, Olga Iarovaia, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphomaJean-Marie Michot, Alice Buet-Elfassy, Maxime Annereau, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2018
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progressionA Bernard-Tessier, C Baldini, Patricia Martin, et al.
Pageof 21